Roivant Sciences
1D
1W
1M
3M
YTD
1Y
5Y
ALL
Why Robinhood?
Robinhood gives you the tools you need to put your money in motion. You can buy or sell ROIV and other ETFs, options, and stocks.About ROIV
Roivant Sciences Ltd. engages in the biopharmaceutical business, which engages in the development of transformative medicine. Its product portfolio includes Vtama, Batoclimab, Brepocitinib, Namilumab, and RVT-2001, which aims to treat psoriasis, atopic dermatitis, thyroid eye disease, and other illnesses.
CEOMatthew Gline
CEOMatthew Gline
Employees750
Employees750
HeadquartersLondon, Greater London
HeadquartersLondon, Greater London
Founded2021
Founded2021
Employees750
Employees750
ROIV Key Statistics
Market cap16.21B
Market cap16.21B
Price-Earnings ratio-39.99
Price-Earnings ratio-39.99
Dividend yield—
Dividend yield—
Average volume7.59M
Average volume7.59M
High today$22.80
High today$22.80
Low today$21.39
Low today$21.39
Open price$21.77
Open price$21.77
Volume12.39M
Volume12.39M
52 Week high$22.80
52 Week high$22.80
52 Week low$8.73
52 Week low$8.73
Stock Snapshot
The current Roivant Sciences(ROIV) stock price is $22.80, with a market capitalization of 16.21B. The stock trades at a price-to-earnings (P/E) ratio of -39.99.
On 2025-12-13, Roivant Sciences(ROIV) stock moved within a range of $21.39 to $22.80. With shares now at $22.80, the stock is trading +6.6% above its intraday low and 0.0% below the session's peak.
Trading volume for Roivant Sciences(ROIV) stock has reached 12.39M, versus its average volume of 7.59M.
Over the past 52 weeks, Roivant Sciences(ROIV) stock has traded between a high of $22.80 and a low of $8.73.
Over the past 52 weeks, Roivant Sciences(ROIV) stock has traded between a high of $22.80 and a low of $8.73.
Analyst ratings
91%
of 11 ratingsBuy
90.9%
Hold
9.1%
Sell
0%
People also own
Based on the portfolios of people who own ROIV. This list is generated using Robinhood data, and it’s not a recommendation.